Elizabeth Hudson
5.7K posts

Elizabeth Hudson
@ClarkPolner
Founder @ Ambitious Bio. fmr @yale; industrial robotics @symbotic; Advisory Board @centerforastro; Intel @usnavy





I’m guessing it would be cheaper for the US to just buy Lilly and give all US citizens GLP1s for free than continue to drown in long term Medicare/Medicaid/healthcare costs.






Many people don't understand the scale @SecWar is demanding. The United States has built less than 40,000 cruise missiles, ever, since the Army asked the Dayton-Wright Company to manufacture an Aerial Torpedo in 1917. The more time passes, the fewer we make and the more they cost. Leaders like DepSecWar Feinberg and @USWREMichael are actually responding to foreign threats and giving clear demand signal that is bringing billions of dollars of private capital into solving this problem. Now America will manufacture more cruise missiles in the next three years than the last 30 years combined, at a fraction of the cost. We are in the middle of hiring for Barracuda production at Arsenal-1 starting later this year, please hit us up if this mission is one you can be passionate about.


@captgouda24 The prostitute comment is quite apt. God made men differ in strength, but Sam Colt made them equal. Likewise, God made men differ in intelligence, but Sam Altman made them equal. We’re now competing on beauty. The concern is not if scaling has hit a wall. It’s if you have.

I've said it before: the bottleneck is not speed. This DNA model is 275x faster, but it creates a tree of life that groups drosophila with plants. How is AI going to solve cancer if it can't get the most basic biology right?


I know a few teachers in Queens who would beg to differ.


SITUATION DETECTED: Demis Hassabis said at Google I/O that solving all disease is close, as Google unveiled Gemini for Science.




I'm super excited to announce our $7.2M seed round + a strategic collaboration with @PacBio! Together, we'll be generating long-read, bulk-RNA sequencing directly from patient tumours spanning multiple cancer indications. This is extremely rich data that will be used to further train and evaluate our models. @blankbio_, we are focused on training RNA foundation models that can learn and predict disease progression and treatment response in patients. These are the biological insights that will enable us to design smaller, more efficient clinical trials with higher success rates. Huge thank you to all of our investors who have been amazing supporters from the beginning. For more details, please check out the links below. Press release: blank.bio/seed-announcem… Blog from the team: blank.bio/accelerate-cli… We're hiring: ycombinator.com/companies/blan…




